Local injection of adalimumab for perianal Crohn's disease: Better than infliximab?

Inflammatory Bowel Diseases

Volumn 16, Issue 10, 2010, Pages 1631-

  Poggioli, G ^a   Laureti, S ^a   Pierangeli, F ^a   Bazzi, P ^a   Coscia, M ^a   Gentilini, L ^a   Gionchetti, P ^a   Rizzello, F ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

CROHN DISEASE; DOSE CALCULATION; FIBROSIS; HUMAN; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIANAL ABSCESS; PRIORITY JOURNAL; PROCTOCOLITIS; RECURRENT DISEASE; SCAR; SEPSIS; SURGICAL DRAINAGE; TREATMENT CONTRAINDICATION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANUS DISEASES; CROHN DISEASE; HUMANS; INJECTIONS; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649274942     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21210     Document Type: Letter

References (2)

1. Poggioli G, Laureti S, Pierangeli F, et al. Local injection of infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum. 2005; 48: 768-774.
2. Poggioli G, Laureti S, Campieri M, et al. Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag. 2007; 3: 301-308.